About this trial
The purpose of this study is to assess the efficacy of an LGBTQ-affirmative individual cognitive behavioral psychotherapy (CBT) and LGBTQ-affirmative family therapy (attachment-based family therapy for sexual and gender minority young adults; ABFT-SGM) delivered via telehealth to a sample of sexual and gender minority adults with nonaccepting parent(s) in New York, Pennsylvania, Connecticut, and Israel. The investigators will assess whether both treatments are associated with significant decreases in depressive and anxiety symptoms. The investigators will also assess whether and how each treatment achieves reductions in mental health symptoms through specific mechanisms (e.g., rejection sensitivity, internalized stigma, emotion dysregulation, parental rejection and acceptance).
Eligibility criteria
Qualifiers
be 20 and older
be fluent in English
self-identify as lesbian, bisexual, queer, pansexual, or other non-heterosexual identity
currently experience elevated depressive or anxiety symptoms (screened initially using a cutoff of ≥ 2.5 on the Brief Symptom Inventory-4 and further confirmed by the BDI and BAI).
Disqualifiers
report current mental health treatment ≥1 day/month (except for medication management ≤1 day/week)
report beginning a new medication within the past 30 days
exhibit active psychosis or active mania, as assessed by the SCID-Psych Screen.
exhibit active suicidality or active homicidality, as assessed by the SIDAS
Trial design
Treatments tested in this trial
- LGBTQ-affirmative CBT
- ABFT-SGM
Treatment groups
Sponsors and collaborators
Yale University
Lead sponsor
Ben-Gurion University of the Negev
Collaborator
Israel Science Foundation
Collaborator